Endothelial factors and autoregulation during pressure changes in isolated newborn piglet cerebral arteries.
To analyze newborn cerebrovascular autoregulation, middle cerebral arteries from 3-4-d-old piglets were cannulated, and diameter changes after transmural pressure variation were measured. After an equilibration period at 30 mm Hg, pressure was modified from 10 to 70 mm Hg in 20-mm Hg steps. Segments with endothelium showed vasodilation during pressure decrease and vasoconstriction during pressure increase. In each case the maximum response was about 5% that of the resting diameter. Segments without endothelium responded passively to pressure change. Vasodilation during pressure decrease was reduced by the preferential calcium-activated potassium (KCa) channel blocker, tetraethylammonium (1 mM), and was absent with the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine methylester (L-NAME, 10 microM). The NO synthase substrate, L-arginine (10 microM), counteracted the dilation blockade caused by L-NAME. The cyclooxygenase inhibitor indomethacin (10 microM) and the endothelin A receptor antagonist BQ-123 (10O microM) eliminated the pressure increase-induced vasoconstriction. The ATP-sensitive potassium channel blocker, glibenclamide (1 microM), and the endothelin B receptor antagonist, BQ-788 (10 nM), did not modify the autoregulatory response. None of these drugs modified the passive changes produced by pressure variations in segments without endothelium. These results suggest that: 1) piglet middle cerebral artery autoregulation is endothelium-dependent; 2) NO and KCa channels are involved in vasodilation during transmural pressure decrease, and 3) endothelin-1, through endothelin A receptors, and prostanoids mediate vasoconstriction during pressure increase.
Servicio de Pediatría, Hospital Virgen de la Luz, Cuenca, Spain.
J
J
Martínez-Orgado
R
R
González
M J
MJ
Alonso
M A
MA
Rodríguez-Martínez
C F
CF
Sánchez-Ferrer
J
J
Marín
D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001120:Arginine / Q000494:pharmacology; D002536:Cerebral Arteries / Q000187:drug effects / Q000502:physiology*; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000502:physiology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology; D006706:Homeostasis; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D051036:Large-Conductance Calcium-Activated Potassium Channels; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D026902:Potassium Channel Blockers; D024681:Potassium Channels, Calcium-Activated; D011312:Pressure; D013552:Swine; D019789:Tetraethylammonium / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D004791:Enzyme Inhibitors; D051036:Large-Conductance Calcium-Activated Potassium Channels; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D026902:Potassium Channel Blockers; D024681:Potassium Channels, Calcium-Activated; C086539:BQ 788; D019789:Tetraethylammonium; D001120:Arginine; C072247:cyclo(Trp-Asp-Pro-Val-Leu); D005905:Glyburide; D019331:NG-Nitroarginine Methyl Ester; D007213:Indomethacin